Results 31 to 40 of about 47,533 (300)

miR-135a promotes gastric cancer progression and resistance to oxaliplatin

Oncotarget, 2016
Resistance to oxaliplatin (OXA)-based chemotherapy regimens continues to be a major cause of gastric cancer (GC) recurrence and metastasis. We analyzed GC samples and matched non-tumorous control stomach tissues from 280 patients and found that miR-135a was overexpressed in GC samples relative to control tissues.
Lin‐Hai Yan, Zhi-Ning Chen, Li-Li Li-Li, Jia Chen, Wene Wei, Xianwei Mo, Yuzhou Qin, Yuan Lin, Jiansi Chen   +8 more
openalex   +4 more sources

KIAA1199 promotes oxaliplatin resistance and epithelial mesenchymal transition of colorectal cancer via protein O-GlcNAcylation

Translational Oncology, 2023
Oxaliplatin is a commonly used platinum drug for colorectal cancer (CRC). However, the treatment of CRC by oxaliplatin usually fails because of drug resistance, which results in a huge challenge in the therapy of CRC.
Qingling Hua, Yuanyuan Lu, Dingxiang Wang, Jie Da, Wanren Peng, Guoping Sun, Kangsheng Gu, Hua Wang, Yanzhe Zhu   +8 more
doaj   +1 more source

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance [PDF]

Molecular Cancer Therapeutics, 2015
AbstractOxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming a standard in the management of this malignancy. It is also considered for the treatment of pancreatic and gastric cancers. However, a major reason for treatment failure still is the existence of tumor intrinsic or acquired resistance. Consequently,
Eva, Martinez-Balibrea, Anna, Martínez-Cardús, Alba, Ginés, Vicenç, Ruiz de Porras, Catia, Moutinho, Laura, Layos, José Luis, Manzano, Cristina, Bugés, Sara, Bystrup, Manel, Esteller, Albert, Abad   +10 more
openaire   +4 more sources

Construction and Validation of an Oxaliplatin-Resistant Gene Signature in Colorectal Cancer Patients Who Underwent Chemotherapy

Pharmaceuticals, 2022
Aberrant expression of genes contributes to the chemoresistance of colorectal cancer (CRC) treatment. This study aimed to identify genes associated with the chemoresistance of oxaliplatin-based chemotherapy in CRC patients and to construct a signature ...
Yixin Yin, Siqi Li, Xinqiang Liang, Kezhi Li, Mingzhi Xie, Bangli Hu   +5 more
doaj   +1 more source

LRRC8A promotes the initial development of oxaliplatin resistance in colon cancer cells

Heliyon, 2023
Leucine-rich repeat-containing 8 A (LRRC8A) is an essential component of the volume-regulated anion channel (VRAC), which plays a vital role in cell proliferation, migration, apoptosis, and drug resistance.
Haifeng Zhang, Zhenghui Jing, Rong Liu, Yassin Shada, Sindhwani Shria, Shiyu Cui, Yuhua Ren, Yuan Wei, Liangming Li, Shuang Peng   +9 more
doaj   +1 more source

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer

Cancers, 2022
Resistance to treatments is one of the leading causes of cancer therapy failure. Oxaliplatin is a standard chemotherapy used to treat metastatic colorectal cancer. However, its efficacy is greatly reduced by the development of resistances. In a previous study, we deciphered the mechanisms leading to oxaliplatin resistance and highlighted the roles ...
Chocry, Mathieu, Leloup, Ludovic, Parat, Fabrice, Messé, Mélissa, Pagano, Alessandra, Kovacic, Hervé   +5 more
openaire   +2 more sources

Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review [PDF]

Cancer Treatment Reviews, 2007
Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with "cisplatin-resistant" cancer.
Stordal, Britta, Pavlakis, Nick, Davey, Ross   +2 more
openaire   +5 more sources

METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma. [PDF]

Cell Death Differ
Jin X, Lv Y, Bie F, Duan J, Ma C, Dai M, Chen J, Lu L, Xu S, Zhou J, Li S, Bi J, Wang F, Xie D, Cai M.   +14 more
europepmc   +3 more sources

Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer

Signal Transduction and Targeted Therapy, 2022
Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an estimated 50% of patients will eventually stop responding to treatment due to acquired resistance.
Yimin Li, Yaqi Gan, Jiaxin Liu, Juanni Li, Zhengwei Zhou, Ruotong Tian, Ruizheng Sun, Jiaqi Liu, Qing Xiao, Yuanyuan Li, Pengyan Lu, Yulong Peng, Yuqian Peng, Guang Shu, Gang Yin   +14 more
doaj   +1 more source

NLRP3/IL‐1β induced myeloid‐derived suppressor cells recruitment and PD‐L1 upregulation promotes oxaliplatin resistance of hepatocellular carcinoma

MedComm, 2023
Oxaliplatin is commonly used as the first‐line chemotherapeutic agent for advanced hepatocellular carcinoma (HCC). Unfortunately, the acquired resistance, limits the effectiveness of oxaliplatin and the underlying mechanisms remain unknown. Therefore, we
Wenfeng Liu, Feng Zhang, Bing Quan, Fan Yao, Rongxin Chen, Zhenggang Ren, Xin Yin   +6 more
doaj   +1 more source